FrancophonIA/ELRC3.0 huggingface dataset:
English: Overall, the varying affinity for serotoninergic receptors with the different ergot derivatives and the therapeutic doses used may explain the differences observed for notification rates for the fibrotic reactions.
Croatian: Ukupno gledano, promjenjivi afinitet za serotoninergične receptore s različitim derivatima ergota i korištenim terapijskijm dozama može objasniti razlike uočene za stupnjeve notifikacije za fibrotičke reakcije.
English: The data from the reported cases of fibrosis (n=12) are indicative of the capacity of dihydroergocristine to induce fibrotic reactions, mostly localised in the pulmonary area considering also the improvement of some patients following discontinuation of the product.
Croatian: Podaci iz prijavljenih slučajeva fibroze (n=12) ukazuju na sposobnost dihidroergokristina na indukciju reakcije fibroze koje su uglavnom lokalizirane u plućnom području uzimajući također u obzir poboljšanje kod nekih bolesnika nakon prekida terapije lijekom.
English: However, in this study with adequate methodological quality standard, non-significant difference between dihydroergocristine + raubasine and placebo groups was observed.
Croatian: Međutim, u ovom ispitivanju s odgovarajućim metodološkim standardom kvalitete, uočena je beznačajna razlika između skupina koje su primale dihidroergokristin s raubazinom i onih koje su primale placebo.
English: This is indicative of a causal relationship between fibrosis and dihydroergocristine.
Croatian: To ukazuje na uzročnu povezanost između fibroze i dihidroergokristina.
English: While it is agreed that the medical terminology used nowdays and in the past differs and that the data needs to be assessed bearing this aspect in mind, the clinical symptom of dementia is a result of various pathophysiological processes which makes pooling and comparison of the data difficult, especially when the individual studies used slightly different inclusion criteria.
Croatian: Dok je istovremeno zaključeno da je medicinska terminologija koja se koristi danas različita od one koja se koristila nekad i da podatke treba procijeniti imajući i taj aspekt u vidu, klinički simptom demencije je rezultat različitih patofizioloških procesa koji otežavaju grupiranje i usporedbu podataka posebice kod pojedinačnih ispitivanja koja koriste blago različite kriterije uključivanja.
English: The MAHs also submitted their own overviews and critical summaries of all spontaneous reports of fibrotic reactions (cardiac with or without pulmonary arterial hypertension, pulmonary, pleural, peritoneal, retroperitoneal, etc) and ergotism with their ergot derivatives-containing medicinal products.
Croatian: Nositelji odobrenja predali u također svoje preglede i kritička izvješća o fibrotičkim reakcijama (srčane s ili bezhipertenzije plućne arterije, pulmonalne, pleuralne, peritonealne, retroperitonealne i sl) te ergotizam kod lijekova koji sadrže derivate ergota.
English: A scientific advisory group (SAG) was convened in December 2012 at the request of the CHMP during which the experts discussed, based on their clinical experience, whether this substance plays a role in the symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Croatian: Znanstvena savjetodavna skupina (SAG) sazvana je u prosincu 2012. na zahtjev CHMP-a tijekom kojeg su stručnjaci, na temelju svog kliničkog iskustva raspravljali da li tvar igra ulogu u simptomatskom liječenju kroničnog patološkog, kognitivnog i neurosenzorskog oštećenja u starijih (isključujući Alzheimerovu bolesti i druge demencije).
English: Based on these data and based on the pharmacological plausibility, dihydroergocristine is considered to be associated with fibrotic reactions.
Croatian: Na temelju ovih podataka i farmakološke vjerojatnosti, smatra se da je dihidrergokristin povezan s fibrotičkim reakcijama.
English: The most recent study (Vellas 1998 - Not published) that became available after the granting of the initial marketing autohrisation, uses a standardised definition of diagnosis (patients had to present a moderate memory deficit, with a Mini-Mental Sate Examination MMSE > 25 and a score total > 38 and < 70 on the Mac Nair and Kahn auto-questionnaire assessing the difficulties in daily activities) and defines the primary efficacy criterion a priori (the Mac Nair and Kahn auto-questionnaire and the Gröber and Buschke test).
Croatian: Najnovija ispitivanja (Vellas 1998. - nije objavljeno) koja su postala dostupna nakon dobivanja prvog odobrenja za stavljanje lijeka u promet (bolesnici su se prezentirali s umjerenim deficitom memorije, s MMSE (mini pregled mentalnog statusa) većim od 25 i ukupnim rezultatom većim od 38 te manjim od 70 na autoupitniku Mac Naira i Kahna koji procjenjuje poteškoće u svakodnevnim aktivnostima) i apriori definira primarni kriterij djelotvornosti te u skladu s Gröber i Buschkeovim testom).
English: Therefore, even if it is highly pharmacologically plausible that ergot derivatives acting as 5HT2B receptor agonists may induce "serotonergic" valve disease similar to that induced by carcinoid tumours or fibrotic lesions of other tissues, it must be remembered that some ergot derivatives are not 5-HT2B receptor agonists.
Croatian: Stoga čak i ako je uvelike farmakološki vjerojatno da derivati ergota koji djeluju kao agonisti receptora 5-HT2Bmogu potaknuti „serotoninergičnu" bolest zalistaka sličnu onoj izazvanoj karcinoidnim tumorima ili fibrotičkim lezijama drugih tkiva, ne smije se zaboraviti da neki derivati ergota nisu agonisti receptora 5-HT2B.
English: These included limiting treatment duration in certain conditions, contraindicating the product in patients with pre-existing fibrosis or in association with other drugs, the issuing of a DHPC highlighting the risk, a checklist for prescribers, and a pharmacological in vitro study for 5-HT subclass receptors affinity to the product.
Croatian: One uključuju ograničeno trajanje liječenja u određenim uvjetima, što čini lijek kontradiktornim u bolesnika s prethodnom fibrozom ili u vezi s drugim lijekovima, izdavanje DHPC-a koje je istaknulo rizik, lista provjere za propisivače te farmakološka i in vitro ispitivanja afiniteta lijeka prema podklasi receptora 5HT.
English: Even if in some cases, confounding treatment (known to induce fibrotic reaction) have been coadministrated, the relationship between fibrotic reactions observed and treatment with dihydroergocristine cannot be excluded.
Croatian: Ako se čak i u nekim slučajevima primjenjuju kontradiktorne terapije (za koje se zna da potiču fibrotičku reakciju), odnos između uočenih fibrotičkih reakcija i terapija s dihidroergokristinom ne može se isključiti.
English: Therefore, other mechanisms inducing fibrosis cannot be excluded, which suggests a causal link between fibrosis and agonism of 5-HT2A and 5-HT1B receptors and also plausible effect on serotonin transporter.
Croatian: Stoga se ne mogu isključiti drugi mehanizmi koji uključuju fibrozu što ukazuje na uzročnu vezu između fibroze i agonizma 5-HT2A i 5-HT1B receptora te također vjerojatni učinak na transporter serotonina.
English: The CHMP was therefore requested to give its opinion on whether the marketing authorisations for ergot derivatives containing medicinal products should be maintained, varied, suspended or withdrawn in relation to the below mentioned indications:
Croatian: Od CHMP-a se tražilo da izrazi mišljenje o tome je li potrebno održati, izmijeniti, suspendirati ili ukinuti odobrenja za stavljanje u promet lijekova koji sadrže derivate ergota u vezi s indikacijama navedenim u nastavku:
English: From the approved indications of the dihydroergocristine containing medicinal products the ones that are in the scope of this referral procedure and are approved in at least one Member State are the following (specific wording of the indication may vary from product to product):
Croatian: Od odobrenih indikacija za lijekove koji sadrže dihidroergokristin koji spadaju pod djelokrug ove procjene te su odobreni barem u jednoj državi članici su sljedeći (specifične riječi koje se koriste za indikacije razlikuju se od lijeka do lijeka):
English: Ergot derivatives are recognised as being capable of inducing fibrosis, in particular heart valve fibrosis.
Croatian: Prepoznata je sposobnost derivata ergot alkaloida da izazovu fibrozu, posebice fibrozu srčanog zalistka.
English: • The variation to the terms of the marketing authorisation for dihydroergocristine containing medicinal products referred to in Annex I, to delete the below indications from the Product Information (specific wording of the indication may vary from product to product and from country to country) as well as any relevant reference to these indications in the Product Information, when there are other therapeutic indications approved as part of their marketing authorisation:
Croatian: • Izmjenu odobrenja za stavljanje u promet lijekova koji sadrže dihidroergokristin koji su navedeni u Prilogu I. kako bi se izbrisale u nastavku navedene indikacije iz Informacija o lijeku (specifične riječi mogu varirati od lijeka do lijeka i od zemlje do zemlje) kao i bilo koje relevantne reference za ove indikacije u Informacijama o lijeku kada postoje druge terapijske indikacije odobrene kao dio njihova odobrenja za stavljanje lijeka u promet:
English: Moreover, it was pointed out that topical instillations of dihydroergocristine are out of the scope of this procedure.
Croatian: Štoviše, istaknuto je da su topikalne primjene dihidroergokristina izvan djelokruga ovog postupka.
English: Grounds for the variation/suspension to the terms of the marketing authorisations
Croatian: Razlozi za izmjenu/suspenziju uvjeta odobrenja za stavljanje lijeka u promet.
English: − Is not favourable for acute retinopathies of vascular origin.
Croatian: Nije povoljan za akutne retinopatije vaksularnog podrijetla.
English: The relationship between fibrosis and serotininergic receptor activation, particularly 5-HT2B receptors by ergot derivatives is extensively described in the literature.
Croatian: Odnos između fibroze i aktivacije serotoninergičnih receptora 5-HT2B izazvane derivatima ergota detaljno je opisan u literaturi.
English: All the data submitted were reviewed and considered, and though it can be interpreted as suggestive of mild efficacy of dihydroergocristine in the”treatment of chronic cognitive impairment in the elderly”, efficacy cannot be considered as sufficiently demonstrated namely due to the inconsistency of the data generated in the larger trials.
Croatian: Svi predani podaci bili su uzeti u obzir i procijenjeni te se mogu tumačiti kao da ukazuju na blagu djelotvornost dihidroergokristina u „liječenju kroničnog, kognitivnog oštećenja u starijih osoba”, ne može se smatrati da je djelotvornost dostatno dokazana ponajprije zbog nedosljednosti generiranih podataka u većim kliničkim ispitivanjima.
English: Overall summary of the scientific evaluation of dihydroergocristine containing medicinal products (see Annex I)
Croatian: Ukupni sažetak znanstvene procjene lijekova koji sadrže dihidroergokristinin (vidjeti Prilog I.)
English: • Prophylaxis of migraine headache
Croatian: • Profilaksa migrenske glavobolje.
English: For the indications “ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin” and “acute retinopathies of vascular origin”, the few preclinical findings submitted reporting the effects of topical doses of dihydroergocristine were considered by the CHMP insufficient to support the use of dihydroergocristine as intraocular pressure (IOP) lowering agent in human or for other ocular conditions presumably of vascular origin.
Croatian: Za indikacije „pomoćno liječenje pada oštrine vida i smetnji u vidnom polju prvenstveno vaskularnog podrijetla” i „akutnih retinopatija vaskularnog podrijetla”, CHMP je smatrao da su nekoliko podnesenih nekliničkih nalaza koji su zabilježili učinke topikalnih doza dihidroergokristina nedostatni da bi poduprli upotrebu dihidroergokristina kao agensa za snižavanje očnog tlaka (IOP) u ljudi ili za liječenje drugih vaskularnih stanja prvenstveno vaskularnog podrijetla.
English: The MAHs submitted 27 literature references to support the efficacy of dihydroergocristine on the indication “symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)”.
Croatian: Nositelji odobrenja predali su 27 literaturnih referenci kako bi podržali djelotvornost dihidroergokristina za indikaciju „simptomatsko liječenje patoloških, kognitivnih i neurosenzorskih oštećenja u starijih (isključujući Alzheimerovu bolest i druge demencije)”.
English: Additionally one case of retroperitoneal fibrosis was reported in the literature (concerning fibrotic plaque), and a scan performed one year after the discontinuation of dihydroergocristine revealed a marked reduction of the fibrotic plaque which was considered by the CHMP in favour of a causal relationship between the retroperitoneal fibrosis observed and dihydroergocristine.
Croatian: Pored toga u literaturi je zabilježen i jedan slučaj retroperitonealne fibroze (u vezi fibrotičkog plaka) te snimanja koja su se provodila jednom godišnje nakon prekida terapije dihidroergokristinom otkrila su značajnu redukciju fibrotičkog plaka za koju je CHMP smatrao da ide u prilog uočenoj uzročnoj povezanosti retroperitonealne fibroze i dihidroergokristina.
English: • The Committee considered that the benefit-risk balance of dihydroergocristine containing products:
Croatian: • Povjerenstvo je smatralo da omjer dobrobiti i rizika lijekova koji sadrže dihidroergokristin:
English: It should also be underlined that reports of reduction of the extension of the fibrotic plaque a long time after dihydroergocristine withdrawal, improvements after dihydroergocristine discontinuation and positive rechallenge (symptoms re-occurring on readministration) have been reported.
Croatian: Potrebno je također istaknuti da su zabilježena izvješća o redukciji opsega fibrotičkih naslaga dugo vremena nakon prekida liječenja dihidroergokristinom, o poboljšanju zdravstvenog statusa nakon prekida liječenja dihidroergokristinom te ponovnoj pojavi simptoma nakon ponovne primjene lijeka.
English: In addition, on the basis of the reported cases, vasoconstriction induced by dihydroergocristine cannot be excluded.
Croatian: Osim toga, ne može se isključiti vazokonstrikcija izazvana dihidroergokristinom na temelju prijavljenih slučajeva.
English: − Is not favourable for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin.
Croatian: Nije povoljan za pomoćno liječenje smanjenja oštrine vida i poremećaja vidnog polja prvenstveno vaskularnog podrijetla.
English: The Committee concluded that the benefit-risk balance of dihydroergocristine containing products is not favourable pursuant to Article 116 of Directive 2001/83/EC for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia), for ancillary treatment of visual acuity decrease and visual field disturbances presumably of vascular origin and for acute retinopathies of vascular origin.
Croatian: Direktive 2001/83/EZ za simptomatsko liječenje kroničnog, patološkog, kognitivnog i neurosenzorskog oštećenja u starijih (isključujući Alzheimerovu bolest i druge demencije), za pomoćno liječenje smanjenja oštrine vida i poremećaja vidnog polja prvenstveno vaskularnog podrijetla i za liječenje akutnih retinopatija vaskularnog podrijetla.
English: − Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Croatian: • Simptomatsko liječenje kroničnog patološkog, kognitivnog i neurosenzorskog oštećenja u starijih osoba (isključujući Alzheimerovu bolest i druge demencije).
English: − Is not favourable for symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia).
Croatian: Nije povoljan za simptomatsko liječenje kroničnog patološkog, kognitivnog i neurosenzorskog oštećenja u starijih osoba (isključujući Alzheimerovu bolest i druge demencije).
English: In both studies, the majority of patients were adults.
Croatian: U oba ispitivanja sudjelovali su većinom odrasli bolesnici.
English: Systemic formulations of levofloxacin (such as tablets and solutions for infusion) have been authorised in the EU since the 1990s.
Croatian: Sistemske formulacije levofloksacina (kao što su tablete i otopine za infuziju) odobrene su u Europskoj uniji od 1990-ih godina.
English: It must not be used in pregnant or breastfeeding women.
Croatian: Lijek se ne smije upotrebljavati u trudnica i dojilja.
English: Treatment cycles may be repeated for as long as the patient benefits.
Croatian: Terapijski se ciklusi mogu ponavljati sve dok bolesnik ima koristi od terapije.
English: The full EPAR and risk management plan summary for Quinsair can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Quinsair nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: After 28 days of treatment, the patient stops treatment for 28 days, before starting another 28-day treatment.
Croatian: Nakon 28 dana terapije, bolesnik prekida terapiju na 28 dana prije početka novog terapijskog ciklusa od 28 dana.
English: Quinsair levofloxacin
Croatian: Quinsair levofloksacin
English: This is a summary of the European public assessment report (EPAR) for Quinsair.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Quinsair.
English: Other information about Quinsair
Croatian: Ostale informacije o lijeku Quinsair
English: The European Commission granted a marketing authorisation valid throughout the European Union for Quinsair on 26 March 2015.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Quinsair na snazi u Europskoj uniji od 26. ožujka 2015.
English: Because levofloxacin has a potential risk on cartilage, the use of the product was not considered justified in adolescents.
Croatian: Budući da kod primjene levofloksacina postoji potencijalan rizik od oštećenja hrskavice, smatra se da uporaba lijeka nije opravdana u adolescenata.
English: Levofloxacin is a well-known antibiotic.
Croatian: Levofloksacin je poznati antibiotik.
English: It works by blocking enzymes that P. aeruginosa bacteria use to make copies of their DNA during cell multiplication.
Croatian: Djeluje tako da blokira enzime koje bakterija P. aeruginosa koristi za kopiranje svog DNK-a tijekom podjele stanice.
English: What measures are being taken to ensure the safe and effective use of Quinsair?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Quinsair?
English: The most common side effects with Quinsair are cough (seen in 54% of patients), dysgeusia (taste disturbances, 30%) and tiredness/weakness (25%).
Croatian: Najčešće nuspojave povezane s lijekom Quinsair su kašalj (zabilježen u 54% bolesnika), disgeuzija (promijenjen osjet okusa, 30%) i umor/slabost (25%).
English: It is not intended to provide practical advice on how to use Quinsair.
Croatian: Svrha sažetka nije davati praktične savjete o korištenju lijeka Quinsair.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Quinsair nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
English: In addition, the company that markets Quinsair will carry out a study to investigate the long-term safety of Quinsair when used in clinical practice in the European Union.
Croatian: Osim toga, tvrtka koja Quinsair stavlja u promet provest će ispitivanje u kojem će istražiti dugoročnu sigurnost primjene Quinsaira u kliničko praksi u Europskoj uniji.
English: Why is Quinsair approved?
Croatian: Zašto je Quinsair odobren?
English: Before using Quinsair, doctors should consider official guidance on the appropriate use of antibiotics.
Croatian: Prije primjene lijeka Quinsair liječnici trebaju proučiti službene smjernice o odgovarajućoj primjeni antibiotika.
English: Regarding safety, Quinsair was well tolerated with side effects similar to those of levofloxacin given systemically (throughout the body).
Croatian: U pogledu sigurnosti, Quinsair se dobro podnosi, s nuspojavama sličnim onima kod levofloksacina primijenjenog sustavno (u cijelom tijelu).
English: What is Quinsair and what is it used for?
Croatian: Što je Quinsair i za što se koristi?
English: A risk management plan has been developed to ensure that Quinsair is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Quinsair.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Quinsair, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku Quinsair nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Following 28 days of treatment, the patients taking Quinsair had an improvement in FEV1 of 1.73%, while for patients taking placebo the improvement in FEV1 was of around 0.43%.
Croatian: U ispitanika koji su primjenjivali Quinsair nakon 28 dana terapije došlo je do poboljšanja vrijednosti FEV1 od 1,73%, dok je u ispitanika koji su uzimali placebo poboljšanje vrijednosti FEV1 iznosilo 0,43%.
English: The first study, which involved 330 patients, compared Quinsair with placebo (a dummy treatment), while the second, involving 282 patients, compared it with another inhaled antibiotic (tobramycin).
Croatian: U prvom ispitivanju koje je obuhvaćalo 330 ispitanika, Quinsair je uspoređivan s placebom (liječenje bez djelatne tvari), dok je u drugom ispitivanju koje je obuhvaćalo 282 ispitanika, uspoređivan s drugim inhalacijskim antibiotikom (tobramicinom).
English: What are the risks associated with Quinsair?
Croatian: Koji su rizici povezani s lijekom Quinsair?
English: Cystic fibrosis is an inherited disease in which there is an accumulation of thick mucus in the lungs that allows bacteria to grow more easily, causing infections.
Croatian: Cistična fibroza je nasljedna bolest pri kojoj dolazi do akumulacije debelog sloja sluzi u plućima što omogućuje brži rast bakterija, rezultirajući infekcijama.
English: The second study showed that Quinsair was at least as good as tobramycin at improving FEV1 following 1 to 3 treatment cycles.
Croatian: Drugo je ispitivanje pokazalo da je Quinsair u najmanju ruku jednako djelotvoran kao tobramicin u poboljšanju vrijednosti FEV1 nakon 1 do 3 terapijska ciklusa.
English: The CHMP considered that the modest improvement in FEV1 seen with Quinsair meant that it could help to meet the need for additional inhaled antibiotics to treat long-term P. aeruginosa infections in cystic fibrosis.
Croatian: CHMP smatra da skromno poboljšanje vrijednosti FEV1 uslijed primjene Quinsaira znači da ovaj lijek može zadovoljiti potrebu za dodatnim antibioticima koji se inhaliraju za liječenje dugotrajnih infekcija uzrokovanih bakterijom P. aeruginosa kod cistične fibroze.
English: However, the study failed to show that Quinsair is more effective than placebo at increasing the time it took before the patients had an exacerbation (flare-up) of their disease.
Croatian: Međutim, u ispitivanju nije dokazano da je Quinsair djelotvorniji od placeba u produljenu razdoblja do pogoršanja (razbuktavanja) bolesti.